Is there a link between prior antibiotic therapy and tigecycline resistance?

Why do antibiotics like vancomycin affect tigecycline susceptibility?

Prior antibiotic exposure can shift bacterial populations toward reduced tigecycline susceptibility. Vancomycin therapy correlates with higher MICs to tigecycline in enterococci, where increased vancomycin MICs also raise tigecycline MICs. This observation comes from studies tracking MIC distributions in isolates from patients who received multiple antibiotics.

What happens to bacteria inside patients who received multiple courses of antibiotics?

Bacteria recovered from patients after prolonged or repeated antibiotic courses show higher rates of tigecycline nonsusceptibility. The observation holds for methicillin-resistant Staphylococcus aureus, methicillin-sensitive Staphylococcus aureus, and enterococci. Bacteria isolated from patients with prior vancomycin or linezolid exposure display tigecycline MICs that sometimes reach or exceed the FDA breakpoint of 0.5 mg/L.

Can tigecycline work against bacteria that already resist other antibiotics?

Tigecycline retains activity against many multidrug-resistant isolates. It shows strong in vitro activity against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. However, isolates that gained resistance during tigecycline therapy itself show cross-resistance patterns that already existed before tigecycline exposure, rather than new mechanisms triggered solely by tigecycline.

How does prior linezolid use influence spätere tigecycline resistance reports?

Linezolid exposure appears in patient histories of cases where bacteria gained tigecycline nonsusceptibility. These reports describe patients who received linezolid before isolation of nonsusceptible strains. The observation suggests a possible association between linezolid exposure and subsequent tigecycline nonsusceptibility, but the data remain observational rather than causal.

When does the FDA set the susceptibility breakpoint for tigecycline?

The FDA establishes the susceptibility breakpoint for tigecycline at 0.5 mg/L for Staphylococcus aureus and 0.5 mg/L for enterococci.